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respectively) and higher incremental QALY benefits (0.18 versus 0.15 respectively.
CONCLUSIONS: The identification of patient characteristics associated with
greater potential for health gain and reduced cost is an important goal. The anal-
ysis of PLD alongside simulation model output provides an additional mechanism
for informing health care decision-making.
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OBJECTIVES: Performing face validation and internal validation of health eco-
nomic models is recommended by various guidelines, including ISPOR, in model
development and is essential in determining a model’s credibility. Using third
parties – individuals outside of the model building process with no stake in model
results – is considered a best practice when conducting these validations. Yet the
rate at which published models follow this practice is unknown. This study reviews
the extent to which third parties were reported used to conduct face and internal
validity in published literature. METHODS: The study reviewed 100 health eco-
nomic models chosen randomly from published peer-reviewed health economic
literature within the last eight years. Decision analysis, Markov models, and dis-
crete event simulation models were included in the review. Each model was re-
viewed to determine the extent to which face validation and internal validation
were performed. Next, it was noted if these validations were performed by third
parties. Surveys were conducted with a subsample of models not reporting valida-
tion to determine if: 1) validation was performed but not reported; 2) if unreported
validation was performed by a third party; 3) any reason(s ) for not performing
validation; and 4) reasons for not using third parties. RESULTS: Third party face
validation and internal validation were each reported in less than one-third of the
studies reviewed. Survey results also found that third party validation was seldom
performed. Reasons for not performing third party validations included: believing
that third party validation was not necessary, time constraints, and budget
constraints. CONCLUSIONS: While considered a best practice, third party face and
internal validations are seldom performed on published economic models. Creat-
ing more awareness regarding this best practice may increase utilization of third
parties. Finding ways to perform these validations in a less costly and more timely
manner may increase usage as well.
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OBJECTIVES: To develop a conceptual model (CM) of COPD using Delphi method-
ology and to describe qualitative associations between disease attributes and their
impact on progression and outcomes. METHODS: An earlier literature review did
not identify any comprehensive CM of COPD that could be used in economic mod-
elling. A draft CM was developed based on literature and expert opinion and vali-
dated using Delphi methodology. Five experienced US and European COPD experts
were recruited and asked to describe the relationships between COPD disease at-
tributes (measurable aspects of the disease that impact on disease progression or
outcomes) included in the model using two rounds of questionnaires. Experts were
asked 1) whether the attributes included in the draft CM were relevant in explain-
ing disease progression, 2) how these attributes are associated (direction of rela-
tionship) with other attributes, 3) assess the strength of attribute-outcome rela-
tionships and 4) add additional attributes if required. Delphi results were reviewed
by a steering group of health economists, epidemiologists and clinicians to deter-
mine the attributes where sufficient evidence exists for use in economic modelling.
RESULTS: Attributes included in the final CM are exacerbations, lung function,
exercise capacity, signs/symptoms (cough, sputum, dyspnoea), co-morbidities
(CVD and depression), body composition (BMI), biomarkers (fibrinogen), smoking
history and demographic characteristics (age, gender). Mortality and quality of life
were agreed to be the most relevant (final) outcome measures. Infection, environ-
mental factors, social status and ethnicity were excluded due to lack of available
evidence to quantify their impact on disease progression and outcomes.
CONCLUSIONS: A CM should be developed prior to defining the structure of an
economic model. We developed a CM that reflects the heterogeneous nature of the
disease by including a wide variety of COPD attributes that have an impact disease
progression. Evidence is available to quantify the impact of the selected attributes
on economic, humanistic and clinical outcomes.
PRM57
DEVELOPING BASDAI AND BASFI PREDICTIVE EQUATIONS FROM CLINICAL
TRIAL DATA OF GOLIMUMAB FOR SEVERE, ACTIVE ANKYLOSING SPONDYLITIS
IN ADULTS
Chaudhary MA1, Hsu B2, Muszbek N3, Proskorovsky I4, Farrell J5
1Merck Research Laboratories, North Wales, PA, USA, 2Janssen R&D, Inc., Spring House, PA,
USA, 3United BioSource Corporation, Budapest, Hungary, 4United BioSource Corporation, Dorval,
QC, Canada, 5MSD, Hoddesdon, Hertfordshire, UK
OBJECTIVES: GO-RAISE clinical trial has shown Golimumab to be effective in the
treatment of severe, active ankylosing spondylitis (AS). A Markov model was de-
veloped to predict the outcomes of a cohort of AS patients treated with golimumab
50 mg (Gol) and its comparators over a 20-year time frame based on short-term
clinical trial data. We developed predictive equations for BASDAI (Bath Ankylosing
Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Func-
tional Index) to model long-term AS disease progression. METHODS: Multivariable
predictive equations of the mean change from baseline in BASDAI and BASFI scores
up to 24 weeks , and between 24–108 weeks were developed using a systematic
approach to investigate the possible non-linear functional relationships in combi-
nation with backward elimination. Fractional polynomials technique was em-
ployed to find appropriate time parameterization. To account for within-patient
correlation, a repeated measures mixed-effect model was used. Baseline score,
time and interaction of time and treatment were considered as potential predictors
along with age, sex and treatment group. Goodness of fit was evaluated with sta-
tistical and graphical methods. RESULTS: 1/Time^2 was identified as the best time
parameterization for change in both BASDAI and BASFI over the first 24 weeks. The
models depicted continuous though slight improvement in patients treated with
Gol and no change after the first eight weeks in patients treated with placebo. Log
time was identified as the best time parameterization for change in BASDAI/BASFI
from week 28 to week 108 in Gol responders group. Being on active treatment,
higher score at baseline, and male gender were associated with greater reduction in
BASDAI and BASFI score. The fitted models provided a good fit.CONCLUSIONS:The
predicted equations based on robust statistical methodology can be utilized to
model long-term AS disease progression in patients treated with anti-TNF inhib-
itors.
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OBJECTIVES: The IMS CORE Diabetes Model (CDM) is an extensively validated sim-
ulation model designed for use in both for type 1 diabetes mellitus (T1DM) and type
2 diabetes mellitus (T2DM) studies. Validation to external studies is an important
part of demonstrating model credibility, however, many studies are conducted
over a relatively short period. As the CDM is widely used to estimate long-term
clinical outcomes in diabetes patients the objective of this study was to validate the
CDM to contemporary outcomes data; including those with a 20-30 year time
horizon. METHODS: A total of 81 validation simulations were performed stratified
by duration of study follow-up (long-term defined as  15 years follow-up); for
long-term results simulation cohorts representing baseline DCCT and UKPDS co-
horts were generated and intensive and conventional treatment arms were defined
in the CDM. Predicted versus observed macrovascular and microvascular compli-
cations and all cause mortality were assessed using the coefficient of determina-
tion (R2) goodness of fit measure. RESULTS: Across all validation studies the CDM
simulations produced an R2 goodness of fit statistic of 0.90. For validation studies
with duration of follow-up15 years the CDM achieved R2 values of 0.9 and 0.88 for
T1DM and T2DM respectively. In T1DM, validating to 30-year outcomes data re-
sulted in an R2 of 0.72; for long-term 20-year validation to UKPDS in T2DM an R2 of
0.92 was obtained. CONCLUSIONS: This study supports the CDM as a credible tool
for predicting the absolute number of clinical events in DCCT and UKPDS like
populations. With increasing incidence of diabetes worldwide this is of particular
importance for health care decison makers for whom the robust evaluation of
alternative health care policies and therapeutic options is essential.
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OBJECTIVES: The need for differential discounting for costs and health outcomes
has captured the attention of many health economists. The commonly used meth-
odology for both health and money assumes a constant discount rate. The latter is
however scarcely backed up by empirical evidences on time-preference. We aim to
validly gather and interpret empirical data for a representative sample of the Dutch
population on time preference regarding different future time point. METHODS:
Sampling of 850 individuals was managed by Samplingsurvey International (Rotter-
dam NL, www.surveysamplinginternational.com). Web-based questionnaires
were developed paying particular attention to the way questions would be per-
ceived. Questions and analysis were based on a pilot study with considerations on
the possibility to elicit time preference separately for money and health and the
possibility to elicit indifference amounts for different time points in the future
regarding money and quality of life. Exclusion factor was based on the Von New-
man-Morgenstern rationality axioms assuming that consumption at different
times are different consumptions. Further sorting involved the individual’s opti-
mistic or pessimistic views about the future. RESULTS: Time-preferences for both
money and quality of life decrease, with the rate of decline also decreasing, over
increasing time of delay. The time-preference for income was found to be higher
than that of health. Individuals with low health states had higher discount rates.
Females elicited higher discount rates than males. As expected, in the short term,
optimistic individuals had higher discount rates than pessimistic ones; although
this may reverse in the longer term. More importantly, discount rate for income
was higher than that for quality of life. CONCLUSIONS: Empirical evidence col-
lected in this research indicated, similar to the pilot study, that time preferences
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